FDA Approves Repeat Treatment for iDose TR Glaucoma Implant
Glaukos receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options.
/ 3 items
#GKOS↓
Glaukos Stock Drops on Slower iDose Growth Despite Strong Q4 Results
Glaukos shares fell 9% after Q4 iDose sales growth disappointed investors, though the company maintained its 2026 revenue guidance of $600-620 million.
Wells Fargo Upgrades Glaukos: Hidden Growth Driver Spotted
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.